Sponsor content
217 result(s) found, displaying 51 to 60
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
Cancellation by sponsorRequested by Roche Products Pty Ltd
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ACTEMRA SC tocilizumab (rch) 162 mg/0.9 mL solution for injection pre-filled pen ACTPen Autoinjector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ACTEMRA SC tocilizumab (rch) 162 mg/0.9 mL solution for injection pre-filled syringe.
-
Prescription medicine registrationActive ingredients: obinutuzumab.
-
Prescription medicine decision summaryTGA decision: Gavreto (pralsetinib) is provisionally approved to treat adults with advanced or metastatic rearranged during transfection- fusion positive thyroid cancer.
-
Prescription medicine registrationActive ingredients: pralsetinib.
-
Prescription medicine registrationActive ingredients: pralsetinib.